Humacyte, Inc.

HUMA Nasdaq SEC CIK 1818382
Follow Humacyte Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1M +36.5% vs same quarter last year
Net income −$15.5M +11.3% vs same quarter last year
EPS, diluted −$0.06 +45.5% vs same quarter last year
Operating cash flow −$15M +37.4% vs same quarter last year
Revenue by quarter
$0
$517K
$301K
$753K
$467K
$495K
$406K
$1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$40.8M
FY24−$148.7M
FY23−$110.8M
FY22−$12M
FY21−$26.5M
FY20−$66.5M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$105.9M
FY24−$99.7M
FY23−$75.6M
FY22−$72.2M
FY21−$81.4M
FY20−$55.9M
FY19-